New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 29, 2014
05:34 EDTPFE, BAYRY, MRKFDA: Bayer's Aleve may carry lower cardiac risk than others, WSJ reports
The FDA says that a review of popular painkillers found that naproxen, sold as Aleve by Bayer, may carry a lower cardiac risk than similar painkilling drugs, reports the Wall Street Journal.Reference Link
News For BAYRY;PFE;MRK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
February 26, 2015
11:35 EDTBAYRYBayer reports FY14 net income EUR 3.43B vs. EUR 3.19B last year
Subscribe for More Information
09:41 EDTMRKHospira launches generic Remicade, WSJ says
Subscribe for More Information
06:30 EDTBAYRYBayer says flotation of MaterialScience 'proceeding on schedule'
Subscribe for More Information
February 25, 2015
08:08 EDTMRKMerck to present new data from IMPROVE-IT, TRA 2P studies
Subscribe for More Information
February 24, 2015
08:07 EDTPFEPfizer announces Trumenba studies met primary objectives
Subscribe for More Information
05:17 EDTMRKMerck collaborates with Medicines Patent Pool to expand Raltegravir access
Subscribe for More Information
February 23, 2015
08:27 EDTMRKNGM Biopharmaceuticals to hold a teleconference
NGM Biopharm discusses the strategic collaboration with Merck to discover, develop and commercialize novel biologic therapeutics on a teleconference to be held on February 23 at 9:30 am. Webcast Link
07:04 EDTMRKMerck, NGM Biopharmaceuticals announce multi-year collaboration
NGM Biopharmaceuticals and Merck announced they have entered into a multi-year collaboration to research, discover, develop and commercialize novel biologic therapies across a wide range of therapeutic areas. This agreement will become effective upon the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act. The collaboration includes multiple drug candidates currently in preclinical development at NGM, including NP201, which is being evaluated for the treatment of diabetes, obesity and nonalcoholic steatohepatitis. NGM will lead the research and development of the existing preclinical candidates and have the autonomy to identify and pursue other discovery stage programs at its discretion. Merck will have the option to license all resulting NGM programs following human proof of concept trials. If Merck exercises this option, Merck will lead global product development and commercialization for the resulting products, if approved. Under the terms of the agreement, Merck will make an upfront payment to NGM of $94M and will purchase a 15 percent equity stake in NGM for $106M at a price per share that represents a 20% premium to NGMs most recent financing. Merck will commit up to $250M to fund all of NGMs efforts under the initial five-year term of the collaboration, with the potential for additional funding if certain conditions are met. Prior to Merck initiating a Phase 3 study for a licensed program, NGM may elect to either receive milestone and royalty payments or, in certain cases, to co-fund development and participate in a global cost and revenue share arrangement of up to 50%. The agreement also provides NGM with the option to participate in the co-promotion of any co-funded program in the United States. Merck will have the option to extend the research agreement for two additional two-year terms.
February 20, 2015
10:33 EDTPFEBattleground update: AbbVie named top global pick at Jefferies
Subscribe for More Information
10:31 EDTPFEPfizer announces FDA acceptance of NDA for Rapamune
Pfizer announced that the FDA has accepted for priority review a supplemental New Drug Application for RAPAMUNE for the treatment of lymphangioleiomyomatosis, a rare, progressive lung disease in women of childbearing age that is often fatal. With the Priority Review designation for the sNDA, Pfizer anticipates a decision in June of 2015 based on the anticipated Prescription Drug User Fee Act action date. The sNDA is based on results from the Multicenter International Lymphangioleiomyomatosis Efficacy and Safety of Sirolimus Trial. The MILES Trial included 89 LAM patients with moderate lung impairment who were randomized to receive RAPAMUNE or placebo for 12 months, followed by a 12 month observation period. In the trial, those treated with RAPAMUNE for one year experienced stabilization of lung function as measured by forced expiratory volume in one second.
07:23 EDTBAYRY, PFEAbbVie replaces Pfizer as top global pharma pick at Jefferies
Subscribe for More Information
07:08 EDTMRKAmerican Academy of Allergy, Asthma and Immunology to hold annual meeting
2015 Annual Meeting of AAAAI is being held in Houston, Texas on February 20-24.
06:29 EDTBAYRYBayer close to selling diabetes unit to Panasonic, Bloomberg says
Subscribe for More Information
February 19, 2015
18:25 EDTBAYRY, PFEPiper Jaffray biotech analyst to hold analyst/industry conference call
Subscribe for More Information
16:50 EDTBAYRYSanofi appoints Olivier Brandicourt CEO
Subscribe for More Information
14:53 EDTBAYRYBayer near sale of diabetes unit to KKR backed venture, Bloomberg says
Subscribe for More Information
14:49 EDTPFEWalgreens selected by Pfizer as one of pharmacies to dispense Ibrance
Subscribe for More Information
14:01 EDTBAYRYBayer near sale of diabetes unit to KKR's Panasonic Healthcare, Bloomberg says
Subscribe for More Information
08:38 EDTMRKNewLink reports clinical development milestone achieved with Merck for rVSV-EBOV
NewLink Genetics (NLNK) announced that it had received notification from Merck (MRK) that the milestone event specified in the license and collaboration agreement between the two companies relating to the further development of the rVSV-EBOV, Ebola, vaccine candidate had been achieved. Under the terms of the agreement, NewLink Genetics will receive a payment of $20M in connection with the achievement of the milestone. The milestone pertains to the initiation of a key clinical trial for the vaccine.
07:12 EDTPFEWharton Health Care Club to hold a conference
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use